Detalles de la búsqueda
1.
Genomics to select treatment for patients with metastatic breast cancer.
Nature
; 610(7931): 343-348, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36071165
2.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
N Engl J Med
; 386(6): 556-567, 2022 02 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35139274
3.
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Breast Cancer Res Treat
; 2024 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38453781
4.
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Int J Gynecol Cancer
; 34(4): 550-558, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38129136
5.
Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
Int J Cancer
; 152(5): 921-931, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36161271
6.
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
Oncologist
; 28(10): e867-e876, 2023 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37589218
7.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 23(11): 1367-1377, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36183733
8.
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.
Breast Cancer Res Treat
; 191(1): 191-207, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34687411
9.
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Gynecol Oncol
; 164(2): 254-264, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34952708
10.
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
Gynecol Oncol
; 166(3): 389-396, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35902297
11.
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
Gynecol Oncol
; 164(1): 18-26, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34696892
12.
Unhealthy behaviors after breast cancer: Capitalizing on a teachable moment to promote lifestyle improvements.
Cancer
; 127(15): 2774-2787, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33887074
13.
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Lancet Oncol
; 21(5): 699-709, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32305099
14.
Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET).
Angiogenesis
; 23(2): 193-202, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31773439
15.
Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials.
Br J Cancer
; 122(6): 759-765, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32001832
16.
Improvement in adherence to Capecitabine and Lapatinib by way of a therapeutic education program.
Support Care Cancer
; 28(7): 3313-3322, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31758323
17.
Quality of life for older patients with cancer: a review of the evidence supporting melatonin use.
Aging Clin Exp Res
; 32(12): 2459-2468, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32236899
18.
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
Int J Cancer
; 145(12): 3359-3369, 2019 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31087564
19.
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.
Br J Cancer
; 121(12): 991-1000, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31719684
20.
Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Breast Cancer Res Treat
; 173(2): 397-406, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30357526